179 related articles for article (PubMed ID: 32343165)
1. Direct-acting antivirals in relapsed or refractory hepatitis C virus-associated diffuse large B-cell lymphoma.
Merli M; Defrancesco I; Visco C; Besson C; Di Rocco A; Arcari A; Sica A; Cencini E; Tisi MC; Frigeni M; Grossi P; Bianchi B; Mora B; Bertù L; Bruno R; Passamonti F; Arcaini L
Leuk Lymphoma; 2020 Sep; 61(9):2122-2128. PubMed ID: 32343165
[TBL] [Abstract][Full Text] [Related]
2. Direct-Acting Antivirals in Hepatitis C Virus-Associated Diffuse Large B-cell Lymphomas.
Merli M; Frigeni M; Alric L; Visco C; Besson C; Mannelli L; Di Rocco A; Ferrari A; Farina L; Pirisi M; Piazza F; Loustaud-Ratti V; Arcari A; Marino D; Sica A; Goldaniga M; Rusconi C; Gentile M; Cencini E; Benanti F; Rumi MG; Ferretti VV; Grossi P; Gotti M; Sciarra R; Tisi MC; Cano I; Zuccaro V; Passamonti F; Arcaini L
Oncologist; 2019 Aug; 24(8):e720-e729. PubMed ID: 30552159
[TBL] [Abstract][Full Text] [Related]
3. Concomitant therapy with direct-acting antivirals and chemoimmunotherapy in HCV-associated diffuse large B-cell lymphoma.
Occhipinti V; Farina L; Viganò M; Capecchi M; Labanca S; Fanetti I; Corradini P; Rumi M
Dig Liver Dis; 2019 May; 51(5):719-723. PubMed ID: 30502232
[TBL] [Abstract][Full Text] [Related]
4. Biological features and outcome of diffuse large B-cell lymphoma associated with hepatitis C virus in elderly patients: Results of the prospective 'Elderly Project' by the Fondazione Italiana Linfomi.
Arcari A; Tabanelli V; Merli F; Marcheselli L; Merli M; Balzarotti M; Zilioli VR; Fabbri A; Cavallo F; Casaluci GM; Tucci A; Puccini B; Pennese E; Di Rocco A; Zanni M; Flenghi L; Gini G; Sartori R; Chiappella A; Usai SV; Tani M; Marino D; Arcaini L; Vallisa D; Spina M
Br J Haematol; 2023 May; 201(4):653-662. PubMed ID: 36733229
[TBL] [Abstract][Full Text] [Related]
5. Antiviral therapies for managing viral hepatitis in lymphoma patients.
Merli M; Rattotti S; Gotti M; Arcaini L
Expert Opin Pharmacother; 2017 Mar; 18(4):363-376. PubMed ID: 28140702
[TBL] [Abstract][Full Text] [Related]
6. Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients.
Cabibbo G; Celsa C; Calvaruso V; Petta S; Cacciola I; Cannavò MR; Madonia S; Rossi M; Magro B; Rini F; Distefano M; Larocca L; Prestileo T; Malizia G; Bertino G; Benanti F; Licata A; Scalisi I; Mazzola G; Di Rosolini MA; Alaimo G; Averna A; Cartabellotta F; Alessi N; Guastella S; Russello M; Scifo G; Squadrito G; Raimondo G; Trevisani F; Craxì A; Di Marco V; Cammà C;
J Hepatol; 2019 Aug; 71(2):265-273. PubMed ID: 30959157
[TBL] [Abstract][Full Text] [Related]
7. Direct-Acting Antivirals as Primary Treatment for Hepatitis C Virus-Associated Indolent Non-Hodgkin Lymphomas: The BArT Study of the Fondazione Italiana Linfomi.
Merli M; Rattotti S; Spina M; Re F; Motta M; Piazza F; Orsucci L; Ferreri AJM; Perbellini O; Dodero A; Vallisa D; Pulsoni A; Santoro A; Sacchi P; Zuccaro V; Chimienti E; Russo F; Visco C; Zignego AL; Marcheselli L; Passamonti F; Luminari S; Paulli M; Bruno R; Arcaini L;
J Clin Oncol; 2022 Dec; 40(35):4060-4070. PubMed ID: 35714311
[TBL] [Abstract][Full Text] [Related]
8. Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection.
Arcaini L; Besson C; Frigeni M; Fontaine H; Goldaniga M; Casato M; Visentini M; Torres HA; Loustaud-Ratti V; Peveling-Oberhag J; Fabris P; Rossotti R; Zaja F; Rigacci L; Rattotti S; Bruno R; Merli M; Dorival C; Alric L; Jaccard A; Pol S; Carrat F; Ferretti VV; Visco C; Hermine O
Blood; 2016 Nov; 128(21):2527-2532. PubMed ID: 27605512
[TBL] [Abstract][Full Text] [Related]
9. High rates of hepatitis C virus (HCV) cure using direct-acting antivirals in HIV/HCV-coinfected patients: a real-world perspective.
Hawkins C; Grant J; Ammerman LR; Palella F; Mclaughlin M; Green R; Mcgregor D; Stosor V
J Antimicrob Chemother; 2016 Sep; 71(9):2642-5. PubMed ID: 27330060
[TBL] [Abstract][Full Text] [Related]
10. [The Current Status and Research Progress of Antiviral Therapy in HCV-Associated Lymphoma --Review].
Sun XH; Wan S; Li ZJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Dec; 29(6):1987-1990. PubMed ID: 34893147
[TBL] [Abstract][Full Text] [Related]
11. The influence of immunosuppressants on direct-acting antiviral therapy is dependent on the hepatitis C virus genotype.
Frey A; Piras-Straub K; Walker A; Timm J; Gerken G; Herzer K
Transpl Infect Dis; 2018 Feb; 20(1):. PubMed ID: 29111569
[TBL] [Abstract][Full Text] [Related]
12. [Recurrence of malignant lymphoma immediately after treatment for hepatitis C virus using direct-acting antivirals].
Iwane K; Kayahara T; Takabatake H; Morimoto Y; Iseki A; Mizuno M; Notohara K
Nihon Shokakibyo Gakkai Zasshi; 2019; 116(2):177-183. PubMed ID: 30745556
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis C virus and diffuse large B-cell lymphoma: Pathogenesis, behavior and treatment.
Visco C; Finotto S
World J Gastroenterol; 2014 Aug; 20(32):11054-61. PubMed ID: 25170194
[TBL] [Abstract][Full Text] [Related]
14. Achieving a high cure rate with direct-acting antivirals for chronic Hepatitis C virus infection in Cameroon: a multi-clinic demonstration project.
Coyer L; Njoya O; Njouom R; Mossus T; Kowo MP; Essomba F; Boers A; Coutinho R; Ondoa P;
Trop Med Int Health; 2020 Sep; 25(9):1098-1109. PubMed ID: 32502290
[TBL] [Abstract][Full Text] [Related]
15. Direct-acting antivirals in hepatitis C virus (HCV)-infected and HCV/HIV-coinfected patients: real-life safety and efficacy.
Milazzo L; Lai A; Calvi E; Ronzi P; Micheli V; Binda F; Ridolfo AL; Gervasoni C; Galli M; Antinori S; Sollima S
HIV Med; 2017 Apr; 18(4):284-291. PubMed ID: 27477612
[TBL] [Abstract][Full Text] [Related]
16. Lymphomas associated with chronic hepatitis C virus infection: A prospective multicenter cohort study from the Rete Ematologica Lombarda (REL) clinical network.
Rattotti S; Ferretti VV; Rusconi C; Rossi A; Fogazzi S; Baldini L; Pioltelli P; Balzarotti M; Farina L; Ferreri AJM; Laszlo D; Speziale V; Varettoni M; Sciarra R; Morello L; Tedeschi A; Frigeni M; Defrancesco I; Zerbi C; Flospergher E; Nizzoli ME; Morra E; Arcaini L;
Hematol Oncol; 2019 Apr; 37(2):160-167. PubMed ID: 30726562
[TBL] [Abstract][Full Text] [Related]
17. Treatment of chronic genotype-3 hepatitis C virus infection using direct-acting antiviral agents: An Indian experience.
Goel A; Bhargava R; Rai P; Aggarwal R
Indian J Gastroenterol; 2017 May; 36(3):227-234. PubMed ID: 28656492
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs.
Llaneras J; Riveiro-Barciela M; Lens S; Diago M; Cachero A; García-Samaniego J; Conde I; Arencibia A; Arenas J; Gea F; Torras X; Luis Calleja J; Antonio Carrión J; Fernández I; María Morillas R; Rosales JM; Carmona I; Fernández-Rodríguez C; Hernández-Guerra M; Llerena S; Bernal V; Turnes J; González-Santiago JM; Montoliu S; Figueruela B; Badia E; Delgado M; Fernández-Bermejo M; Iñarrairaegui M; Pascasio JM; Esteban R; Mariño Z; Buti M
J Hepatol; 2019 Oct; 71(4):666-672. PubMed ID: 31203153
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathologic characteristics and outcomes of transformed diffuse large B-cell lymphoma in hepatitis C virus-infected patients.
Hosry J; Miranda RN; Samaniego F; Economides MP; Torres HA
Int J Cancer; 2018 Mar; 142(5):940-948. PubMed ID: 29047108
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis C Virus-associated Cryoglobulinemic Livedo Reticularis Improved with Direct-acting Antivirals.
Yokoyama K; Kino T; Nagata T; Miyayama T; Shibata K; Fukuda H; Yamauchi R; Fukunaga A; Umeda K; Takata K; Tanaka T; Shakado S; Sakisaka S; Imafuku S; Hirai F
Intern Med; 2023 Dec; 62(24):3631-3636. PubMed ID: 37121750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
